Anthony Welters Joins Gilead Sciences’ Board of Directors
October 22 2020 - 12:15PM
Business Wire
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that
Anthony Welters has been appointed to the company’s Board of
Directors.
Mr. Welters retired in 2016 as Senior Adviser to the Office of
the CEO of UnitedHealth Group (UHG), an organization that serves
more than 100 million people worldwide through its health and
well-being companies. During his tenure at UHG, Mr. Welters served
as Executive Vice President and a Member of the Office of the CEO
and led the company’s Public and Senior Markets Group. He joined
UHG following its acquisition of AmeriChoice, a healthcare company
he founded in 1989. He currently serves on the public boards of
Loews Corporation and the Carlyle Group. He is the Executive
Chairman of the BlackIvy Group, an organization focused on building
and growing commercial enterprises in Sub-Saharan Africa; Chairman
of Somatus, Inc., a value-based care company; and a member of the
Board of Directors for Parachute Health, a healthcare technology
platform company for clinicians, insurance companies and medical
supply distributors. Mr. Welters is also Trustee Emeritus of the
Morehouse School of Medicine Board of Trustees, Chairman Emeritus
of the Board of New York University School of Law, as well as Vice
Chairman of the Board of New York University and a Trustee of NYU
Langone Medical Center.
“We are very pleased to welcome Tony Welters to our Board of
Directors,” said Daniel O’Day, Chairman and Chief Executive Officer
of Gilead Sciences. “Tony understands the urgency of delivering
exceptional healthcare to communities most in need. His extensive
experience in the health insurance and managed care industry will
bring important perspective to our board as we continue our work to
deliver transformational medicines to patients.”
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical
company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The company strives to
transform and simplify care for people with life-threatening
illnesses around the world. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City,
California.
For more information on Gilead Sciences, please
visit the company’s website at www.gilead.com, follow Gilead on
Twitter (@GileadSciences) or call Gilead Public Affairs at
1-800-GILEAD-5 or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201022005919/en/
Douglas Maffei, PhD, Investors (650) 522-2739
Marni Kottle, Media (650) 522-5388
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024